Antares Pharma (NASDAQ:ATRS) and IRadimed (NASDAQ:IRMD) Direct Inquiry


IRadimed (NASDAQ:IRMD – Get Rating) and Antares Pharma (NASDAQ:ATRS – Get Rating) are both small cap medical companies, but which is the best investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, risk, earnings and valuation.

Benefits and evaluation

This table compares the gross revenues, earnings per share and valuation of IRadimed and Antares Pharma.

Gross revenue Price/sales ratio Net revenue Earnings per share Price/earnings ratio
Iradimed $41.81 million 12.50 $9.32 million $0.74 56.23
Antares Pharma $183.98 million 5.15 $46.29 million $0.27 20.63

Antares Pharma has higher revenues and profits than IRadimed. Antares Pharma trades at a lower price-to-earnings ratio than IRadimed, indicating that it is currently the more affordable of the two stocks.


This table compares the net margins, return on equity and return on assets of IRadimed and Antares Pharma.

Net margins Return on equity return on assets
Iradimed 22.30% 13.92% 12.07%
Antares Pharma 25.16% 12.33% 7.83%

Institutional and insider ownership

40.2% of IRadimed shares are held by institutional investors. Comparatively, 48.6% of Antares Pharma shares are held by institutional investors. 48.1% of Iradimed shares are held by insiders. Comparatively, 6.4% of Antares Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds, and large money managers believe a company is poised for long-term growth.

Risk and Volatility

IRadimed has a beta of 0.81, suggesting its stock price is 19% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 1.52, suggesting its stock price is 52% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for IRadimed and Antares Pharma, as reported by

Sales Ratings Hold odds Buy reviews Strong buy odds Rating
Iradimed 0 0 1 0 3.00
Antares Pharma 0 5 0 0 2.00

IRadimed currently has a consensus target price of $42.00, indicating a potential upside of 1.30%. Antares Pharma has a consensus target price of $5.60, indicating a potential upside of 0.54%. Given IRadimed’s stronger consensus rating and higher possible upside, stock analysts clearly believe that IRadimed is more favorable than Antares Pharma.


IRadimed beats Antares Pharma on 9 of the 14 factors compared between the two stocks.

About IRadimed (Get a rating)

IRADIMED CORPORATION develops, manufactures, markets and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories and services in the United States and internationally. It offers an MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI-compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, lateral vehicle pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales managers, clinical support representatives and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

About Antares Pharma (Get a rating)

Antares Pharma logoAntares Pharma, Inc., a specialty pharmaceutical company, is primarily focused on developing and commercializing pharmaceutical products and technologies that meet patient needs in targeted therapeutic areas. It develops, manufactures and markets new therapeutic products using its drug delivery systems. The Company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult men; OTREXUP a subcutaneous injection of methotrexate indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who wake up at least twice a night to urinate. Its injection products also include generic Epinephrine Injection USP products indicated for the emergency treatment of severe allergic reactions, including anaphylaxis in adult and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraines and cluster headaches in adults; and the Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm labor in women, as well as teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid-induced osteoporosis in men and women. Additionally, the company is developing disposable injection pens for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult men; and drugs/devices for urologic oncology, immunology and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.

Get news and reviews for IRadimed Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for IRadimed and related companies with’s FREE daily newsletter.


About Author

Comments are closed.